Eli Lilly opens R&D center in Boston Seaport
- Eli Lilly (NYSE:LLY) has opened a research and development facility in the Boston Seaport to advance its work in RNA and DNA-based therapies, as well as discover new drug targets.
- The Lilly Seaport Innovation Center spreads over 346,000 sq ft and can accommodate around 500 scientists and researchers, in addition to 200 people from the drugmaker’s Gateway Labs’ companies.
- The facility features laboratories and office space and will also house the first Lilly Gateway Labs location on the East Coast.
- Shares of Eli Lilly (LLY) were marginally up premarket on Tuesday and have gained over 49% year-to-date.